The abstract is read at the publisher; the summary is JClub's.
A fully human CD371-directed CD28/CD3ζ CAR T-cell with VH-VL scFv orientation and IL-18 secretion shows improved in vivo survival, especially with H5L linkers.
- Why it matters: Relapsed or refractory AML has poor outcomes, and CD371 is enriched on leukemic stem and chemoresistant cells while being less prevalent on HSCs, motivating a targeted, less toxic approach.
- What they did: The team optimized CAR design (VH-VL vs VL-VH; three to five linkers, including H5L) and tested IL-18–armored activity in vitro and in vivo, including CD34+ umbilical cord blood HSC colony-forming assays.
- The result: IL-18 secretion augmented efficacy against antigen-high and antigen-low/negative tumors, with IL-18–armored CAR T-cells showing superior activity linked to bystander killing via increased interferon-γ and FAS-L upregulation, and reduced HSC toxicity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.